Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says
Executive Summary
If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.
You may also be interested in...
Amarin's First Amendment Victory Could Cut Both Ways For Industry
Companies will have to weigh prospect of freer discussion with health care providers about off-label uses with the risk that FDA and the courts will not see their statements as truthful and non-misleading.
Amarin's First Amendment Victory Could Cut Both Ways For Industry
Companies will have to weigh prospect of freer discussion with health care providers about off-label uses with the risk that FDA and the courts will not see their statements as truthful and non-misleading.
Off-Label Promotion Ruling Presents Hidden Risks For Pharma Companies, Lawyers Say
An appeals court ruling that bars prosecution solely for speech promoting off-label use carries with it potential negative ramifications for the pharmaceutical industry, including liability under state consumer protection laws and greater government scrutiny of internal marketing documents.